Inceptionr LLC Makes New $685,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Inceptionr LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 887 shares of the biopharmaceutical company’s stock, valued at approximately $685,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after acquiring an additional 1,144,887 shares in the last quarter. Nuveen LLC increased its position in shares of Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Regeneron Pharmaceuticals by 8,620.0% during the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after acquiring an additional 656,845 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Royal Bank Of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, Cantor Fitzgerald dropped their price objective on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $787.88.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of REGN stock opened at $656.01 on Friday. The business’s fifty day moving average is $635.78 and its 200-day moving average is $714.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The stock has a market cap of $69.35 billion, a PE ratio of 15.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the previous year, the firm earned $8.22 EPS. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.